1800 244 735

Helpline (02) 9874 9777

HD Service at Westmead approved to participate in 2 new drug trials

 

The Huntington Disease Service at Westmead Hospital has been approved to participate in two new drug trials, called PRECISION-HD1 and PRECISION-HD2. Each study tests a separate Huntingtin-lowering (also known as gene silencing) agent. They are run by a company called Wave Life Sciences based in Massachusetts, USA. The studies involve lumbar punctures, MRI scans, assessments and questionnaires.

These are Phase 1b/2a trials, meaning that they are testing an experimental treatment in humans for the first time. The main goal is to assess whether the treatments are safe and well tolerated in the treatment of Huntington’s disease when compared with a placebo control. Participants must be between the ages of 25-65, have early stage Huntington’s disease, and meet additional criteria.

The study has already commenced overseas. Information can be found at https://clinicaltrials.gov/ct2/show/NCT03225833?recrs=a&cond=huntington%27s+disease&draw=2&rank=16 and https://clinicaltrials.gov/ct2/show/NCT03225846?recrs=a&cond=huntington%27s+disease&draw=2&rank=15. It is expected that together the two studies will involve approximately 96 people worldwide.

If you would like more information, you can call the Huntington Disease Service at Westmead on 0456 740 612. The phone will be monitored on Mondays and Thursdays. Please leave a message if we do not answer when you call.

Huntington’s NSW & ACT and the Huntington Disease Service at Westmead will continue to provide updates on HD research through the Huntington’s NSW & ACT website and Facebook page

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest News and Stories

PGT will be available for Huntington’s families

Published date: 18 May, 2021

Huntington’s families now have several options when considering when and how to have children. One of these options is PGD – Pre-implantation Genetic Diagnosis, sometimes known as PGT. This allows people to use IVF technology to ensure that only embryos without the HD-causing mutation are implanted, meaning that these children will grow up HD-free.

A 4000km cycle to Broome

Published date: 19 April, 2021

Erica and Bill are about to set off on a cycle to Broome. Erica will be the support driver for her partner Bill as they cover over 4000km to reach Broome in June. We are so grateful that you have chosen to fundraise for us.

OUR SUBMISSION to the Joint Standing Committee on the NDIS inquiry into Independent Assessments

Published date: 6 April, 2021

Huntington’s Associations in NSW/ACT, QLD, WA, SA/NT and TAS have partnered with other groups representing people with various neurological diseases to make a joint submission to the Joint Standing Committee on the National Disability Insurance Scheme inquiry into independent assessments under the NDIS. In summary, we do not support the introduction of independent assessments in ... Read more

WAVE PRECISION-HD clinical trials stopped

Published date: 6 April, 2021

An open letter to the Australian Huntington’s community following the 29 March 2021 press release from Wave Life Sciences: On March 29, 2021, Wave Life Sciences issued a press release regarding their PRECISION-HD clinical trials, which are ongoing in Australia and several other countries globally. The key information from the press release is that for ... Read more

An Open Letter to the Australian Huntington’s Community

Published date: 25 March, 2021

Since the news from Roche came out, Australian clinicians, state organisation leaders, and Huntington’s researchers have been meeting on teleconferences to discuss what this means for the Australian Huntington’s disease community.

Generation HD1 trial halted

Published date: 23 March, 2021

The Roche clinical trial called Phase III Generation HD1 has been halted, not by Roche, but by an independent data monitoring committee.